Chemical Name: Ceramidase, glucosyl-(human HT-1080 cell)
Molecular Formula: C2532H3854N672O711S16
CAS Number: 0884604-91-5
Medically reviewed on Mar 22, 2017
Uses for Velaglucerase Alfa
Velaglucerase Alfa Dosage and Administration
Administer under the supervision of a clinician.1
For solution compatibility information, see Compatibility under Stability.
Administer by IV infusion.1
Administer using an inline, low-protein-binding, 0.2-µm particulate filter.1
Determine number of vials to be reconstituted based on patient weight.1
Reconstitute appropriate number of vials containing 400 units of velaglucerase alfa lyophilized powder with 4.3 mL of sterile water for injection, respectively, to provide a solution containing 100 units/mL.1 Mix gently; do not shake.1
Rate of Administration
Administer over 1 hour.1
Children and adolescents ≥4 years of age: 60 units/kg every 2 weeks.1
Adjust dosage based on achievement and maintenance of patient's therapeutic goals.1
Patients receiving imiglucerase can be switched to velaglucerase alfa at an equivalent dosage.1
60 units/kg every 2 weeks.1
Adjust dosage based on achievement and maintenance of the patient's therapeutic goals; dosages ranging from 15–60 units/kg every 2 weeks were evaluated in clinical trials.1
Patients receiving imiglucerase can be switched to velaglucerase alfa at an equivalent dosage.1
Cautions for Velaglucerase Alfa
No known contraindications.1
Hypersensitivity reactions, including anaphylaxis, reported.1
Manage hypersensitivity reactions based on severity.1 If anaphylaxis or other severe hypersensitivity occurs, discontinue velaglucerase alfa immediately and initiate appropriate therapy.1 For mild reactions, may reduce infusion rate, temporarily interrupt infusion, and/or administer antihistamines, antipyretics, and/or corticosteroids.1 Ensure that appropriate medical support is readily available during administration.1
Premedication with antihistamines and/or corticosteroids may prevent subsequent reactions in patients who have experienced a reaction to velaglucerase alfa or other enzyme replacement therapy.1
As with all therapeutic proteins, there is a potential for immunogenicity with velaglucerase alfa therapy.1 Development of IgG antibodies to velaglucerase alfa reported in at least one patient.1 Relationship between such antibodies and hypersensitivity risk not known.1
Continue to monitor for antibodies in patients with an immune response to other enzyme replacement therapies who are switched to velaglucerase alfa.1
Not known whether velaglucerase alfa is distributed into milk.1 Use with caution.1 Consider the known benefits of breast-feeding along with the woman's clinical need for velaglucerase alfa and any potential adverse effects of the drug or disease on the infant.1
Safety and efficacy not established in children <4 years of age.1
Clinical response and adverse effects in geriatric patients appear to be similar to those of younger adults; in general, select dosage with caution in geriatric patients.1
Common Adverse Effects
Hypersensitivity reactions, headache, dizziness, pyrexia, abdominal pain, back pain, joint pain, asthenia/fatigue, prolonged aPTT, nausea.1
Interactions for Velaglucerase Alfa
Formal drug interaction studies not performed to date.1
Velaglucerase Alfa Pharmacokinetics
Accumulation not observed in patients receiving 60 units/kg every 2 weeks for 37 weeks.1
Not known whether velaglucerase alfa distributes into milk.1
Powder for Injection
Following reconstitution or dilution, 2–8°C for up to 24 hours; protect from light; do not freeze.1
For information on systemic interactions resulting from concomitant use, see Interactions.
Sodium chloride 0.9%
Gaucher disease is an autosomal recessive lysosomal storage disorder characterized by a deficiency of the enzyme glucocerebrosidase, which results in accumulation of glucocerebroside within the lysosomes of macrophages in the liver, spleen, bone marrow, and other organs; clinical manifestations include hepatosplenomegaly, anemia, thrombocytopenia, and skeletal complications (e.g., osteopenia, osteonecrosis, progressive joint destruction, fractures).1 3 4 13 34
Enzyme replacement therapy in patients with type 1 Gaucher disease increases the degradation of glucocerebroside to glucose and ceramide, with resultant reduction in liver and spleen size, amelioration of anemia and thrombocytopenia, decreased bone pain, decreased cachexia, and increased bone remineralization over a period of several years.4 7 8 9 12 13 14 15 16 17 18 19
Advice to Patients
Risk of hypersensitivity reactions, including anaphylaxis.1 Advise patients of the possible signs and symptoms of a hypersensitivity reaction and to seek immediate medical care if such manifestations occur.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
For injection, for IV infusion
AHFS DI Essentials. © Copyright 2019, Selected Revisions March 22, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
1. Shire Human Genetic Therapies, Inc. VPRIV (velaglucerase alfa for injection) prescribing information. Cambridge, MA; 2015 April.
2. Food and Drug Administration. Cumulative list of orphan drugs designated and/or approved. Rockville, MD; 2009 Jun 8. Available at http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm. Accessed 2011 Dec 14.
3. Burrow TA, Grabowski GA. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Invest. 2011; 1:285-93.
4. Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biologics. 2010; 4:299-313. http://www.ncbi.nlm.nih.gov/pubmed/21209725?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3010821&blobtype=pdf
5. Zimran A, Altarescu G, Philips M et al. Phase 1/2 and extension study of velaglucerase alfa and replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010; 115:4651-6. http://www.ncbi.nlm.nih.gov/pubmed/20299511?dopt=AbstractPlus
6. Beutler E. Gaucher's disease. N Engl J Med. 1991; 325:1354-60. http://www.ncbi.nlm.nih.gov/pubmed/1922238?dopt=AbstractPlus
7. Genzyme Corporation. Cerezyme (imiglucerase) for injection prescribing information. Cambridge, MA; 2003 Mar.
8. Barton NW, Furbish FS, Murray GJ et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 1990; 87:1913-6. http://www.ncbi.nlm.nih.gov/pubmed/2308952?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=53594&blobtype=pdf
9. Anon. Alglucerase for Gaucher’s disease. Med Lett Drugs Ther. 1991; 33:82. http://www.ncbi.nlm.nih.gov/pubmed/1865852?dopt=AbstractPlus
12. Weinreb NJ, Charrow J, Andersson HC et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Register. Am J Med. 2002; 113:112-9. http://www.ncbi.nlm.nih.gov/pubmed/12133749?dopt=AbstractPlus
13. Niederau C, Haussinger D. Gaucher’s disease: a review for the internist and hepatologist. Hepatogastroenterology. 2000; 47:984-7. http://www.ncbi.nlm.nih.gov/pubmed/11020862?dopt=AbstractPlus
14. Charrow J, Andersson HC, Kaplan P et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations. J Pediatrics. 2003; 144:112-20.
15. Rosenthal DI, Doppelt SH, Mankin HL et al. Enzyme therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics. 1995; 96:629-37. http://www.ncbi.nlm.nih.gov/pubmed/7567322?dopt=AbstractPlus
16. Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase form natural and recombinant sources. Ann Intern Med. 1995; 122:33-9. http://www.ncbi.nlm.nih.gov/pubmed/7985893?dopt=AbstractPlus
17. Actelion Pharmaceuticals. Zavesca (miglustat) capsules prescribing information. South San Francisco, CA; 2003 Jul 31.
18. Elstein D, Abrahamov A, Hadas-Halpern I et al. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM. 1998; 91:483-8. http://www.ncbi.nlm.nih.gov/pubmed/9797931?dopt=AbstractPlus
19. Poll LW, Maas M, Terk MR et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol. 2002; 75(Suppl 1):A25-36.
20. Genzyme Corporation, Cambridge, MA: Personal communication.
21. Stahl PD, Rodman JS, Miller MJ et al. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA. 1978; 75:1399-1403. http://www.ncbi.nlm.nih.gov/pubmed/274729?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=411479&blobtype=pdf
22. Beutler E, Kay AC, Saven A et al. Enzyme-replacement therapy for Gaucher’s disease. N Engl J Med. 1991; 325:1809-10. http://www.ncbi.nlm.nih.gov/pubmed/1944489?dopt=AbstractPlus
23. Zimran A, Hadas-Halpern I, Abrahamov A et al. Enzyme-replacement therapy for Gaucher’s disease. N Engl J Med. 1991; 325:1810-1.
24. Barton NW, Brady RO, Murray GJ et al. Enzyme-replacement therapy for Gaucher’s disease. N Engl J Med. 1991; 325:1811. http://www.ncbi.nlm.nih.gov/pubmed/1944490?dopt=AbstractPlus
25. Furbish FS, Blair HE, Shiloach J et al. Enzyme replacement therapy in Gaucher’s disease: large-scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci USA. 1977; 74:3560-3. http://www.ncbi.nlm.nih.gov/pubmed/269414?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=431631&blobtype=pdf
26. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides: II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun. 1965; 18:221-5. http://www.ncbi.nlm.nih.gov/pubmed/14282020?dopt=AbstractPlus
27. Basu A, Prence E, Garrett K et al. Comparison of N-acyl phosphatidylethanolamines with different N-acyl groups as activators of glucocerebrosidase in various forms of Gaucher’s disease. Arch Biochem Biophys. 1985; 243:28-34. http://www.ncbi.nlm.nih.gov/pubmed/3933429?dopt=AbstractPlus
28. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991; 324:1464-70. http://www.ncbi.nlm.nih.gov/pubmed/2023606?dopt=AbstractPlus
29. Beutler E, Kay A, Saven A et al. Enzyme replacement therapy for Gaucher disease. Blood. 1991; 78:1183-9. http://www.ncbi.nlm.nih.gov/pubmed/1878585?dopt=AbstractPlus
30. Parker RI, Barton NW, Read EJ et al. Hematologic improvement in a patient with Gaucher disease on long-term enzyme replacement therapy: evidence for decreased splenic sequestration and improved red blood cell survival. Am J Hematol. 1991; 38:130-7. http://www.ncbi.nlm.nih.gov/pubmed/1951303?dopt=AbstractPlus
31. Barton NW, Brady RO, Dambrosia JM et al. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease. J Pediatr. 1992; 120:277-80. http://www.ncbi.nlm.nih.gov/pubmed/1735829?dopt=AbstractPlus
32. Anon. Velaglucerase (Vpriv) for Gaucher's disease. Med Lett Drugs Ther. 2010; 52:36.
33. Elstein D, Cohn GM, Wang N et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis. 2011; 46:119-23. Epub 2010 Aug 19. http://www.ncbi.nlm.nih.gov/pubmed/20727796?dopt=AbstractPlus
34. Elstein D, Foldes AJ, Zahrieh D et al. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis. 2011; 47:56-61. Epub 2011 May 4. http://www.ncbi.nlm.nih.gov/pubmed/21536468?dopt=AbstractPlus
35. Elstein D, Altarescu G, Maayan H et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem. Blood Cells Mol Dis. 2012; 48:45-50. Epub 2011 Nov 1. http://www.ncbi.nlm.nih.gov/pubmed/22047948?dopt=AbstractPlus
36. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 22-575: Chemistry review(s). From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000chemr.pdf
More about velaglucerase alfa
- Velaglucerase alfa Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- En Español
- 1 Review
- Drug class: lysosomal enzymes
Other brands: VPRIV